PH12018502457B1 - Treatment for parkinson's disease - Google Patents

Treatment for parkinson's disease

Info

Publication number
PH12018502457B1
PH12018502457B1 PH12018502457A PH12018502457A PH12018502457B1 PH 12018502457 B1 PH12018502457 B1 PH 12018502457B1 PH 12018502457 A PH12018502457 A PH 12018502457A PH 12018502457 A PH12018502457 A PH 12018502457A PH 12018502457 B1 PH12018502457 B1 PH 12018502457B1
Authority
PH
Philippines
Prior art keywords
alkyl
haloalkyl
hydrogen
disease
parkinson
Prior art date
Application number
PH12018502457A
Other languages
English (en)
Other versions
PH12018502457A1 (en
Inventor
Nitin Krishnaji Damle
Sanjay Nandlalji Mandhane
Manoj Atmaramji Upadhya
Sameer Vishwanath Mehetre
Gajanan Uttamrao Chidrewar
Prabal Sengupta
Trinadha Rao Chitturi
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of PH12018502457A1 publication Critical patent/PH12018502457A1/en
Publication of PH12018502457B1 publication Critical patent/PH12018502457B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PH12018502457A 2016-06-02 2018-11-22 Treatment for parkinson's disease PH12018502457B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201621019087 2016-06-02
IN201621019185 2016-06-02
PCT/IN2017/050224 WO2017208267A1 (en) 2016-06-02 2017-06-02 Treatment for parkinson's disease

Publications (2)

Publication Number Publication Date
PH12018502457A1 PH12018502457A1 (en) 2019-10-21
PH12018502457B1 true PH12018502457B1 (en) 2022-01-12

Family

ID=59388123

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12018502457A PH12018502457B1 (en) 2016-06-02 2018-11-22 Treatment for parkinson's disease

Country Status (26)

Country Link
US (4) US10849887B2 (2)
EP (2) EP3463351B1 (2)
JP (1) JP6974357B2 (2)
KR (1) KR102508288B1 (2)
CN (1) CN109475539B (2)
AU (1) AU2017273415B2 (2)
CL (1) CL2018003431A1 (2)
CY (1) CY1125285T1 (2)
DK (1) DK3463351T3 (2)
ES (1) ES2914782T3 (2)
HR (1) HRP20220683T1 (2)
HU (1) HUE059387T2 (2)
IL (1) IL263188B (2)
LT (1) LT3463351T (2)
MX (1) MX385276B (2)
MY (1) MY193754A (2)
NZ (1) NZ748592A (2)
PH (1) PH12018502457B1 (2)
PL (1) PL3463351T3 (2)
PT (1) PT3463351T (2)
RS (1) RS63243B1 (2)
SG (1) SG11201810294QA (2)
SI (1) SI3463351T1 (2)
SM (1) SMT202200228T1 (2)
UA (1) UA123018C2 (2)
WO (1) WO2017208267A1 (2)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013166295A1 (en) 2012-05-02 2013-11-07 Georgetown University Treating neural disease with tyrosine kinase inhibitors
WO2017208267A1 (en) * 2016-06-02 2017-12-07 Sun Pharma Advanced Research Company Limited Treatment for parkinson's disease
CN110606840A (zh) 2018-06-15 2019-12-24 日产化学株式会社 5-炔基吡啶化合物的制造方法
CN113272308B (zh) 2018-11-20 2025-03-18 乔治敦大学 用于治疗神经退行性、肌退行性和溶酶体贮积病症的组合物和方法
BR112021024835A2 (pt) * 2019-06-11 2022-01-18 Sun Pharma Advanced Res Co Ltd Tratamento para sinuclenopatias
WO2021030783A1 (en) * 2019-08-15 2021-02-18 Duke University Compositions and methods for the treatment cancer and cns disorders
IL300044A (en) 2020-07-31 2023-03-01 Sun Pharma Advanced Res Co Ltd N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl) ethynyl]-benzohydrazide for treatment of alzheimer's disease
US20250275953A1 (en) 2022-05-02 2025-09-04 Sun Pharma Advanced Research Company Ltd. Vodobatinib for reducing progression of parkinson's disease
WO2025058473A1 (ko) 2023-09-14 2025-03-20 주식회사 엑소스템텍 퇴행성 뇌질환 치료 단백질을 포함하는 엑소좀을 이용한 뇌 특이적 퇴행성 뇌질환 치료 단백질 전달 기술

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012208388C1 (en) * 2011-01-21 2017-04-27 Sun Pharma Advanced Research Company Ltd Diarylacetylene hydrazide containing tyrosine kinase inhibitors
WO2013166295A1 (en) 2012-05-02 2013-11-07 Georgetown University Treating neural disease with tyrosine kinase inhibitors
US10150733B2 (en) * 2015-05-18 2018-12-11 Sun Pharma Advanced Research Company Ltd. Amidoheteroaryl aroyl hydrazide ethynes
WO2017208267A1 (en) * 2016-06-02 2017-12-07 Sun Pharma Advanced Research Company Limited Treatment for parkinson's disease

Also Published As

Publication number Publication date
LT3463351T (lt) 2022-06-10
CN109475539A (zh) 2019-03-15
MX385276B (es) 2025-03-18
SI3463351T1 (sl) 2022-07-29
US11813252B2 (en) 2023-11-14
US20190275017A1 (en) 2019-09-12
MX2018014944A (es) 2019-03-07
HUE059387T2 (hu) 2022-11-28
BR112018074439A2 (pt) 2019-03-06
US20220273632A1 (en) 2022-09-01
IL263188A (en) 2018-12-31
IL263188B (en) 2021-08-31
SMT202200228T1 (it) 2022-07-21
CY1125285T1 (el) 2025-03-28
ES2914782T3 (es) 2022-06-16
KR20190015257A (ko) 2019-02-13
US20240066014A1 (en) 2024-02-29
UA123018C2 (uk) 2021-02-03
EP4085912A1 (en) 2022-11-09
JP2019520344A (ja) 2019-07-18
CA3024976A1 (en) 2017-12-07
MY193754A (en) 2022-10-27
CL2018003431A1 (es) 2019-05-10
US11583522B2 (en) 2023-02-21
SG11201810294QA (en) 2018-12-28
CN109475539B (zh) 2021-12-28
EP3463351A1 (en) 2019-04-10
JP6974357B2 (ja) 2021-12-01
US10849887B2 (en) 2020-12-01
HRP20220683T1 (hr) 2022-07-08
WO2017208267A1 (en) 2017-12-07
EP3463351B1 (en) 2022-04-27
PL3463351T3 (pl) 2022-06-20
KR102508288B1 (ko) 2023-03-09
AU2017273415A1 (en) 2018-12-06
DK3463351T3 (da) 2022-06-07
PT3463351T (pt) 2022-06-02
US20210015805A1 (en) 2021-01-21
RS63243B1 (sr) 2022-06-30
AU2017273415B2 (en) 2023-01-19
PH12018502457A1 (en) 2019-10-21
NZ748592A (en) 2025-11-28

Similar Documents

Publication Publication Date Title
PH12018502457A1 (en) Treatment for parkinson's disease
MX2019015371A (es) Derivados de dihidro-pirrolo-piridina.
PH12021550310A1 (en) Novel sulfonamideurea compounds
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
MX2020000261A (es) Nuevos compuestos.
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
MY174284A (en) Compounds for treating spinal muscular atrophy
EA201700077A1 (ru) Соединения аминопиримидинила в качестве ингибиторов jak
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
CL2014003181A1 (es) Compuestos derivados de benzamidas n- sustituidas o piridinamidas n-sustituidas; composicion farmaceutica que los comprende; metodo de tratamiento; y su uso para el tratamiento de enfermedades o trastornos seleccionados de dolor, depresion y enfermedades cardiovasculares, respiratorias o psiquiatricas o combinaciones de estas.
CY1125082T1 (el) Υποκατεστημενα τριαζολια και μεθοδοι που σχετιζονται με αυτα
AU2018253590A1 (en) Imidazopyridazine compounds
EA201490269A1 (ru) Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета
TN2017000076A1 (en) N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of nr2b
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
EA201790626A1 (ru) Макроциклические ингибиторы lrrk2-киназы
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
PH12020550168A1 (en) Griseofulvin compound and pharmaceutical use thereof
MX381224B (es) Potentes moduladores de gamma-secretasa.
PH12020551117A1 (en) Compositions for preventing or treating uveitis
MX2019006768A (es) Peptidos antimicrobianos.
EA201590074A1 (ru) Производное бензодиоксола, способ его получения и его применение
PH12019501566A1 (en) Amide compounds and use thereof
EA201892098A1 (ru) Соединение, обладающее ингибирующей мутантную idh активностью, способ его получения и применения
MX337999B (es) Derivados de 8-hidroxiquinolina.